---
title: "Orai1 CRAC Channel Therapeutics: From Molecular Insights to Clinical Progress"
id: "pubmed-42766407"
canonical_url: "https://medichelpline.com/clinical-feed/pubmed-42766407"
content_type: "clinical_feed_article"
specialty: "Critical Care"
source_name: "PubMed / NCBI"
source_url: "https://pubmed.ncbi.nlm.nih.gov/42766407/"
doi: "10.1080/14728222.2026.2738180"
published_at: "2026-09-21T00:00:00.000Z"
evidence_level: "Journal Article"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Orai1 CRAC Channel Therapeutics: From Molecular Insights to Clinical Progress
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/pubmed-42766407
- **Specialty:** [Critical Care](https://medichelpline.com/clinical-feed/critical-care.md)
- **Primary Source:** PubMed / NCBI
- **Source URL:** [Original Journal Publication](https://pubmed.ncbi.nlm.nih.gov/42766407/)
- **DOI:** [10.1080/14728222.2026.2738180](https://doi.org/10.1080%2F14728222.2026.2738180)
- **Published At:** 2026-09-21T00:00:00.000Z
- **Evidence Rating:** Journal Article
## Executive GIST (TL;DR)
- The Ca2+ release-activated Ca2+ (**CRAC**) channel, formed by the interaction of STIM1 and **Orai1**, is the principal mediator of store-operated calcium entry (**SOCE**). Dysregulated SOCE contributes to immune disorders, cancer hallmarks, and other pathologies. - Orai1 is an attractive precision-therapeutic target because of its central role in cellular Ca2+ signalling and disease mechanisms. - Early pharmacological tools (for example, SKF-96365) were nonselective and produced off-target effects, limiting translational potential. - Second-generation pore blockers such as Synta66, RO2959 and GSK-7975A improved selectivity compared with first-generation compounds but retained limitations for clinical use. - Third-generation inhibitors, notably **CM4620 (zegocractin)**, represent a clinical inflection point; the review evaluates Phase 2 clinical trial programs including CARPO (acute pancreatitis), CARDEA (severe COVID-19 pneumonia) and KOURAGE (acute kidney injury). - The review also highlights emerging orally bioavailable candidates (for example, CM5480) intended for chronic cardiopulmonary remodelling and long-term immunomodulation. - Clinical experience indicates that targeting ubiquitous Ca2+ pathways like SOCE requires careful trial design and patient stratification informed by biomarkers. - The authors anticipate a bifurcation in therapeutic strategy: acute intravenous interventions for critical care versus chronic oral immunomodulators for long-term disease. - Future enhancement of therapeutic index may come from exploiting tissue-specific Orai isoform profiles, particularly **Orai2** and **Orai3**, to increase selectivity across disorders. - Overall, the pharmacological trajectory moves from broad chemical tools toward refined, indication-specific agents with an emphasis on biomarker-driven trials and isoform-directed strategies.
## Clinical Analysis & Structured Key Points
Clipboard, Search History, and several other advanced features are temporarily unavailable. [ Skip to main page content ](https://pubmed.ncbi.nlm.nih.gov/42766407/#article-details) ![U.S. flag](https://cdn.ncbi.nlm.nih.gov/coreutils/uswds/img/favicons/favicon-57.png) An official website of the United States government Here's how you know ![Dot gov](https://cdn.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-dot-gov.svg) **The .gov means it’s official.** Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site. ![Https](https://cdn.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-https.svg) **The site is secure.** The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. [ ![NIH NLM Logo](https://cdn.ncbi.nlm.nih.gov/coreutils/nwds/img/logos/AgencyLogo.svg) ](https://www.ncbi.nlm.nih.gov/) [Log in](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F42766407%2F) Show account info Close #### Account Logged in as: **username** * [Dashboard](https://www.ncbi.nlm.nih.gov/myncbi/) * [Publications](https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/) * [Account settings](https://www.ncbi.nlm.nih.gov/account/settings/) * [Log out](https://www.ncbi.nlm.nih.gov/account/signout/?back_url=https%3A//pubmed.ncbi.nlm.nih.gov/42766407/) [Access keys](https://www.ncbi.nlm.nih.gov/guide/browsers/#ncbi_accesskeys) [NCBI Homepage](https://www.ncbi.nlm.nih.gov) [MyNCBI Homepage](https://pubmed.ncbi.nlm.nih.gov/myncbi/) [Main Content](https://pubmed.ncbi.nlm.nih.gov/42766407/#maincontent) [Main Navigation](https://pubmed.ncbi.nlm.nih.gov/42766407/) [ ![pubmed logo](https://cdn.ncbi.nlm.nih.gov/pubmed/c24ab723-7c80-48cd-9c68-022ded852586/core/images/pubmed-logo-blue.svg) ](https://pubmed.ncbi.nlm.nih.gov/) [ ](https://pubmed.ncbi.nlm.nih.gov/42766407/ "Show search bar") Search: [](https://pubmed.ncbi.nlm.nih.gov/42766407/ "Clear search input")Search [Advanced](https://pubmed.ncbi.nlm.nih.gov/advanced/) [ Clipboard ](https://pubmed.ncbi.nlm.nih.gov/clipboard/) [ User Guide ](https://pubmed.ncbi.nlm.nih.gov/help/) Save Email Send to * [ Clipboard ](https://pubmed.ncbi.nlm.nih.gov/42766407/) * [My Bibliography](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F42766407%2F%23open-bibliography-panel) * [Collections](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F42766407%2F%23open-collections-panel) * [Citation manager](https://pubmed.ncbi.nlm.nih.gov/42766407/) Display options Display options Format Abstract PubMed PMID ## Save citation to file Format: Summary (text) PubMed PMID Abstract (text) CSV Create file Cancel ## Email citation Email address has not been verified. Go to [ My NCBI account settings ](https://account.ncbi.nlm.nih.gov/settings/) to confirm your email and then refresh this page. To: Subject: Body: Format: Summary Summary (text) Abstract Abstract (text) MeSH and other data Send email Cancel ### Add to Collections * Create a new collection * Add to an existing collection Name your collection: Name must be less than 100 characters Choose a collection: Unable to load your collection due to an error [Please try again](https://pubmed.ncbi.nlm.nih.gov/42766407/) Add Cancel ### Add to My Bibliography * My Bibliography Unable to load your delegates due to an error [Please try again](https://pubmed.ncbi.nlm.nih.gov/42766407/) Add Cancel ## Your saved search Name of saved search: Search terms: [Test search terms](https://pubmed.ncbi.nlm.nih.gov/42766407/) Would you like email updates of new search results? Saved Search Alert Radio Buttons * Yes * No Email: ([change](https://www.ncbi.nlm.nih.gov/account/settings/)) Frequency: Monthly Weekly Daily Which day? The first Sunday The first Monday The first Tuesday The first Wednesday The first Thursday The first Friday The first Saturday The first day The first weekday Which day? Sunday Monday Tuesday Wednesday Thursday Friday Saturday Report format: Summary Summary (text) Abstract Abstract (text) PubMed Send at most: 1 item 5 items 10 items 20 items 50 items 100 items 200 items Send even when there aren't any new results Optional text in email: Save Cancel ## Create a file for external citation management software Create file Cancel ## Your RSS Feed Name of RSS Feed: Number of items displayed: 5 10 15 20 50 100 Create RSS Cancel RSS Link Copy ### Actions Cite Collections Add to Collections * Create a new collection * Add to an existing collection Name your collection: Name must be less than 100 characters Choose a collection: Unable to load your collection due to an error [Please try again](https://pubmed.ncbi.nlm.nih.gov/42766407/) Add Cancel Permalink Permalink Copy Display options Display options Format Abstract PubMed PMID ### Page navigation * [ Title & authors ](https://pubmed.ncbi.nlm.nih.gov/42766407/#heading) * [ Abstract ](https://pubmed.ncbi.nlm.nih.gov/42766407/#abstract) * [ Plain language summary ](https://pubmed.ncbi.nlm.nih.gov/42766407/#plain-language-summary) * [ Publication types ](https://pubmed.ncbi.nlm.nih.gov/42766407/#publication-types) Title & authors Abstract Plain language summary Publication types Review Expert Opin Ther Targets Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Expert+Opin+Ther+Targets%22%5Bjour%5D&sort=date&sort_order=desc) * [ Search in NLM Catalog ](https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22Expert+Opin+Ther+Targets%22%5BTitle+Abbreviation%5D) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42766407/) . 2026 Sep 21. doi: 10.1080/14728222.2026.2738180. Online ahead of print. # Targeting the Orai1 CRAC channel: translating molecular insights into therapeutic progress [Isaac Jardín](https://pubmed.ncbi.nlm.nih.gov/?term=Jard%C3%ADn+I&cauthor_id=42766407)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42766407/#full-view-affiliation-1 "Department of Physiology \(Cellular Physiology Research Group\), Institute of Molecular Pathology Biomarkers \(IMPB\), Universidad de Extremadura, Spain."), [Alvaro Macias-Díaz](https://pubmed.ncbi.nlm.nih.gov/?term=Macias-D%C3%ADaz+A&cauthor_id=42766407)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42766407/#full-view-affiliation-1 "Department of Physiology \(Cellular Physiology Research Group\), Institute of Molecular Pathology Biomarkers \(IMPB\), Universidad de Extremadura, Spain."), [Vanesa Jimenez-Velarde](https://pubmed.ncbi.nlm.nih.gov/?term=Jimenez-Velarde+V&cauthor_id=42766407)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42766407/#full-view-affiliation-1 "Department of Physiology \(Cellular Physiology Research Group\), Institute of Molecular Pathology Biomarkers \(IMPB\), Universidad de Extremadura, Spain."), [Manuel Fuentes-Mateos](https://pubmed.ncbi.nlm.nih.gov/?term=Fuentes-Mateos+M&cauthor_id=42766407)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42766407/#full-view-affiliation-1 "Department of Physiology \(Cellular Physiology Research Group\), Institute of Molecular Pathology Biomarkers \(IMPB\), Universidad de Extremadura, Spain."), [Tarik Smani](https://pubmed.ncbi.nlm.nih.gov/?term=Smani+T&cauthor_id=42766407)[ 2 ](https://pubmed.ncbi.nlm.nih.gov/42766407/#full-view-affiliation-2 "Group of Cardiovascular Pathophysiology, Institute of Biomedicine of Seville, University Hospital of Virgen Del Rocío/University of Seville/CSIC, Seville, Spain.")[ 3 ](https://pubmed.ncbi.nlm.nih.gov/42766407/#full-view-affiliation-3 "Department of Medical Physiology and Biophysics, Faculty of Medicine, University of Seville, Seville, Spain."), [Juan A Rosado](https://pubmed.ncbi.nlm.nih.gov/?term=Rosado+JA&cauthor_id=42766407)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42766407/#full-view-affiliation-1 "Department of Physiology \(Cellular Physiology Research Group\), Institute of Molecular Pathology Biomarkers \(IMPB\), Universidad de Extremadura, Spain.") Affiliations Expand ### Affiliations * 1 Department of Physiology (Cellular Physiology Research Group), Institute of Molecular Pathology Biomarkers (IMPB), Universidad de Extremadura, Spain. * 2 Group of Cardiovascular Pathophysiology, Institute of Biomedicine of Seville, University Hospital of Virgen Del Rocío/University of Seville/CSIC, Seville, Spain. * 3 Department of Medical Physiology and Biophysics, Faculty of Medicine, University of Seville, Seville, Spain. * PMID: **42766407** * DOI: [ 10.1080/14728222.2026.2738180 ](https://doi.org/10.1080/14728222.2026.2738180) Item in Clipboard Review # Targeting the Orai1 CRAC channel: translating molecular insights into therapeutic progress Isaac Jardín et al. Expert Opin Ther Targets. 2026. Show details Display options Display options Format Abstract PubMed PMID Expert Opin Ther Targets Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Expert+Opin+Ther+Targets%22%5Bjour%5D&sort=date&sort_order=desc) * [ Search in NLM Catalog ](https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22Expert+Opin+Ther+Targets%22%5BTitle+Abbreviation%5D) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42766407/) . 2026 Sep 21. doi: 10.1080/14728222.2026.2738180. Online ahead of print. ### Authors [Isaac Jardín](https://pubmed.ncbi.nlm.nih.gov/?term=Jard%C3%ADn+I&cauthor_id=42766407)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42766407/#short-view-affiliation-1 "Department of Physiology \(Cellular Physiology Research Group\), Institute of Molecular Pathology Biomarkers \(IMPB\), Universidad de Extremadura, Spain."), [Alvaro Macias-Díaz](https://pubmed.ncbi.nlm.nih.gov/?term=Macias-D%C3%ADaz+A&cauthor_id=42766407)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42766407/#short-view-affiliation-1 "Department of Physiology \(Cellular Physiology Research Group\), Institute of Molecular Pathology Biomarkers \(IMPB\), Universidad de Extremadura, Spain."), [Vanesa Jimenez-Velarde](https://pubmed.ncbi.nlm.nih.gov/?term=Jimenez-Velarde+V&cauthor_id=42766407)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42766407/#short-view-affiliation-1 "Department of Physiology \(Cellular Physiology Research Group\), Institute of Molecular Pathology Biomarkers \(IMPB\), Universidad de Extremadura, Spain."), [Manuel Fuentes-Mateos](https://pubmed.ncbi.nlm.nih.gov/?term=Fuentes-Mateos+M&cauthor_id=42766407)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42766407/#short-view-affiliation-1 "Department of Physiology \(Cellular Physiology Research Group\), Institute of Molecular Pathology Biomarkers \(IMPB\), Universidad de Extremadura, Spain."), [Tarik Smani](https://pubmed.ncbi.nlm.nih.gov/?term=Smani+T&cauthor_id=42766407)[ 2 ](https://pubmed.ncbi.nlm.nih.gov/42766407/#short-view-affiliation-2 "Group of Cardiovascular Pathophysiology, Institute of Biomedicine of Seville, University Hospital of Virgen Del Rocío/University of Seville/CSIC, Seville, Spain.")[ 3 ](https://pubmed.ncbi.nlm.nih.gov/42766407/#short-view-affiliation-3 "Department of Medical Physiology and Biophysics, Faculty of Medicine, University of Seville, Seville, Spain."), [Juan A Rosado](https://pubmed.ncbi.nlm.nih.gov/?term=Rosado+JA&cauthor_id=42766407)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42766407/#short-view-affiliation-1 "Department of Physiology \(Cellular Physiology Research Group\), Institute of Molecular Pathology Biomarkers \(IMPB\), Universidad de Extremadura, Spain.") ### Affiliations * 1 Department of Physiology (Cellular Physiology Research Group), Institute of Molecular Pathology Biomarkers (IMPB), Universidad de Extremadura, Spain. * 2 Group of Cardiovascular Pathophysiology, Institute of Biomedicine of Seville, University Hospital of Virgen Del Rocío/University of Seville/CSIC, Seville, Spain. * 3 Department of Medical Physiology and Biophysics, Faculty of Medicine, University of Seville, Seville, Spain. * PMID: **42766407** * DOI: [ 10.1080/14728222.2026.2738180 ](https://doi.org/10.1080/14728222.2026.2738180) Item in Clipboard Cite Display options Display options Format Abstract PubMed PMID ## Abstract **Introduction:** The Ca2+ release-activated Ca2+ (CRAC) channel, triggered by the interaction between the Ca2+ sensor STIM1 and Orai1, is the primary mediator of store-operated calcium entry (SOCE). Dysregulation of this process drives numerous human pathologies, particularly immune disorders and cancer hallmarks. Due to its role, Orai1 has emerged as an attractive target for precision therapeutics. **Areas covered:** This review outlines the pharmacological evolution of CRAC channel modulators, tracing their development from early chemical tools, such as SKF-96365, that exhibits several off-target effects, to more selective second-generation pore blockers, including Synta66, RO2959 or GSK-7975A. Particular attention is paid to third-generation inhibitors, especially CM4620 (zegocractin), evaluating data from recent Phase 2 clinical trials in acute pancreatitis (CARPO), severe COVID-19 pneumonia (CARDEA), and acute kidney injury (KOURAGE). We describe emerging orally bioavailable candidates like CM5480 aimed at chronic cardiopulmonary remodeling. **Expert opinion:** Clinical experience reveals that targeting ubiquitous Ca2+ pathways, such as SOCE, demands specific trial design, transitioning toward biomarker-driven stratification of patient cohorts. Over the coming years, the pharmacological design will diverge into acute intravenous critical care and chronic oral immunomodulation. Ultimately, the exploitation of tissue-specific Orai2 and Orai3 isoform profiles represents the next frontier to enhance therapeutic efficacy across distinct disorders. **Keywords:** CM4620; Calcium-release activated calcium (CRAC) channel; Orai1; Orai3; Store-operated Ca2+ entry. ## Plain language summary Changes in intracellular calcium is an essential signal that controls how our cells work. When calcium levels drop in the intracellular stores, a specific doorway called the Orai channel opens to let calcium back in. In many diseases, calcium entry through these channels is altered, allowing too much calcium to enter and causing cell damage.For decades, scientists used early medicines that blocked this process, but they also interfered with other healthy parts of the body. Recently, researchers have developed smarter, more precise drugs. One leading drug, CM4620, acts like a custom key that temporarily locks only the Orai1 channel. This helps reduce dangerous inflammation in severe conditions such as acute pancreatitis and lung injuryNewer oral versions of these medicines are now being tested to treat long-term diseases, including high blood pressure in the lungs. These targeted therapies offer new hope for treating serious diseases more safely. [PubMed Disclaimer](https://pubmed.ncbi.nlm.nih.gov/disclaimer/) ## Publication types * Review Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Review%22%5Bpt%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Review) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42766407/) [x] Cite Copy Download .nbib .nbib Format: AMA APA MLA NLM **Send To** * [Clipboard](https://pubmed.ncbi.nlm.nih.gov/42766407/) * [Email](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F42766407%2F%23open-email-panel) * [Save](https://pubmed.ncbi.nlm.nih.gov/42766407/) * [My Bibliography](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F42766407%2F%23open-bibliography-panel) * [Collections](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F42766407%2F%23open-collections-panel) * [Citation Manager](https://pubmed.ncbi.nlm.nih.gov/42766407/) [x] NCBI Literature Resources [MeSH](https://www.ncbi.nlm.nih.gov/mesh/) [PMC](https://www.ncbi.nlm.nih.gov/pmc/) [Bookshelf](https://www.ncbi.nlm.nih.gov/books) [Disclaimer](https://pubmed.ncbi.nlm.nih.gov/disclaimer/) The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). Unauthorized use of these marks is strictly prohibited. Follow NCBI [ Twitter ](https://twitter.com/ncbi) [ Facebook ](https://www.facebook.com/ncbi.nlm) [ LinkedIn ](https://www.linkedin.com/company/ncbinlm) [ GitHub ](https://github.com/ncbi) [ ](https://ncbiinsights.ncbi.nlm.nih.gov/) [Connect with NLM](https://www.nlm.nih.gov/socialmedia/index.html) * [ Twitter ](https://twitter.com/NLM_NIH) * [ SM-Facebook ](https://www.facebook.com/nationallibraryofmedicine) * [ SM-Youtube ](https://www.youtube.com/user/NLMNIH) National Library of Medicine [8600 Rockville Pike Bethesda, MD 20894](https://www.google.com/maps/place/8600+Rockville+Pike,+Bethesda,+MD+20894/@38.9959508,-77.101021,17z/data=!3m1!4b1!4m5!3m4!1s0x89b7c95e25765ddb:0x19156f88b27635b8!8m2!3d38.9959508!4d-77.0988323) [Web Policies](https://www.nlm.nih.gov/web_policies.html) [FOIA](https://www.nih.gov/institutes-nih/nih-office-director/office-communications-public-liaison/freedom-information-act-office) [HHS Vulnerability Disclosure](https://www.hhs.gov/vulnerability-disclosure-policy/index.html) [Help](https://support.nlm.nih.gov/?pagename=pubmed%3Apubmed%3Aabstract%3ANONE) [Accessibility](https://www.nlm.nih.gov/accessibility.html) [Careers](https://www.nlm.nih.gov/careers/careers.html) * [NLM](https://www.nlm.nih.gov/) * [NIH](https://www.nih.gov/) * [HHS](https://www.hhs.gov/) * [USA.gov](https://www.usa.gov/)
## Related Clinical Research

- [C5a-C5aR1 axis drives NET formation in SARS-CoV-2 N protein–mediated acute kidney injury](https://medichelpline.com/clinical-feed/pubmed-42468179.md) (DOI: 10.1016/j.bbrc.2026.154305)
- [Multimodal AI model predicts in-hospital mortality for critically ill patients using multicenter I](https://medichelpline.com/clinical-feed/pubmed-42549798.md) (DOI: 10.1097/ALN.0000000000006294)
- [Persistent critical illness in mechanically ventilated acute hypoxic respiratory failure: prevalen](https://medichelpline.com/clinical-feed/plos-one-9-persistent-critical-illness-in-acute-hypoxic-respiratory-failure-a.md)
- [Preadmission factors linked to acute complications, survival and long-term recovery after COVID-19](https://medichelpline.com/clinical-feed/bmj-open-13-defining-the-preadmission-factors-that-modify-risk-of-acute-complications.md)
- [SEROCoV-KIDS cohort: impact of COVID-19 on children and adolescents in Geneva, Switzerland](https://medichelpline.com/clinical-feed/bmj-open-21-cohort-profile-the-serocov-kids-population-based-cohort-study-and-biobank-on.md)

## Navigation
- [← Back to Critical Care Feed](https://medichelpline.com/clinical-feed/critical-care.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.